Lynette Sholl Profile
Lynette Sholl

@lmsholl

Followers
414
Following
50
Media
3
Statuses
67

Joined September 2015
Don't wanna be here? Send us removal request.
@BalazsHalmosMD
Balazs Halmos
4 years
Please see below short outline of emerging biomarkers in cancer management- can you keep up? Maybe we can help along with @lmsholl and our terrific faculty? We even get u a discount: ICOPBH21! What else r u waiting for? This Sat 6/26-ICOP! Even better than IHOP! #PathTwitter
@gotoPER
PER
4 years
Join us for the "5th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards” live, interactive virtual conference on June 26. https://t.co/XG8FAGFxf4 #ICOP
0
3
14
@JLHornick
Jason L. Hornick, M.D., Ph.D.
4 years
1
8
26
@ModernPathology
Modern Pathology
5 years
⭐New #ModPathChat! Ep 4/4 Special Edition #USCAP2021 Long Course: Pulmonary Pathology Dr. @lmsholl discusses w @DrNetto potential role of CD8+ T cell count, Multiplex spatial profiling and novel genomic determinants as markers beyond PD-L1 🎧Podcast: https://t.co/2ZURg9NOUG
0
8
14
@BalazsHalmosMD
Balazs Halmos
5 years
Dizzy from all brand new FDA approvals? Might be opportune time to invite u to our ICOP meeting along w @lmsholl where our amazing faculty will address all your biomarker needs! We'll even have Dr. Tie joining from DownUnder and Dr. Naidoo from X the pond! Pls consider joining!
@gotoPER
PER
5 years
Join us at the "5th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards” live, interactive virtual conference on June 26 to expand your knowledge of new diagnostic techniques. Register now: https://t.co/XG8FAGFxf4
0
8
23
@HMSPostgradCE
Harvard Med Postgraduate and Continuing Education
5 years
Molecular Diagnostics: Current Roles in Cancer Diagnosis and Patient Management will review up-to-date techniques in molecular diagnostics and will delve into the appropriate use of molecular assays for different tumor types. @AlannaChurch_MD @lmsholl https://t.co/IJX7Du4fjD
0
3
4
@lmsholl
Lynette Sholl
5 years
This is not exactly how mTB looks under the microscope... maybe we need to replace our mycobacterial stains @JLHornick @damilnermd >> CDC investigating TB cases linked to tainted bone repair product used in more than 100 patients
Tweet card summary image
washingtonpost.com
The manufacturer of the bone repair product has recalled 154 containers of the material -- a malleable bone putty that is used in a variety of orthopedic procedures.
0
0
5
@lmsholl
Lynette Sholl
5 years
Digital Health Passes in the Age of COVID-19—Are “Vaccine Passports” Lawful and Ethical - a useful medical and legal perspective on this highly politicized topic
1
0
2
@lmsholl
Lynette Sholl
5 years
0
0
0
@BrJCancer
British Journal of Cancer
5 years
Digital Imaging Calls for Papers - open for submissions. Guest Editors: Lynette Sholl and Rulla Tamimi @lmsholl @rtamimi For more details visit: https://t.co/GpvwkuV9XA
0
1
0
@lmsholl
Lynette Sholl
5 years
A big shout out to Suma Thomas and colleagues at CCF: Vitamins won’t make your Covid better. Prevention is the best medicine. Mask! Vaccinate!! Effect of Zinc and Ascorbic Acid on Symptom Length Among Patients With SARS-CoV-2 https://t.co/FcwraqczMK @ClevelandClinic
0
1
4
@sarahjwu
Sarah J. Wu, MD, PhD
5 years
Thanks for highlighting our study! Up front allocation of material for ancillary studies is key to successful biomarker testing. @lmsholl #molpath #WCLC20
@Dr_Ivanoncologo
Dr. Iván R. González
5 years
Implementation of a Lung Biopsy Histology Protocol Supports Successful #CancerBiomarker Testing by @sarahjwu @IASLC @GavinPrestonMD @OncoAlert @StephenVLiu
0
1
6
@lmsholl
Lynette Sholl
5 years
Site-Specific and Targeted Therapy Based on Molecular Profiling for Cancer of Unknown Primary Site https://t.co/oiG9wuQq1f via @JAMAOnc part of @JAMANetwork — highlighting the clinical relevance of genomic profiling in patients with cancers of unknown primary
0
8
18
@UmbertoMalapel1
Umberto Malapelle
5 years
Asthonishing presentation by @ChristianRolfo on the @IASLC #LiquidBiopsy20 statement paper. Antoher step forword to the introduction of liquid biopsy in #NSCLC clinical setting! Eccellente lavoro Christian! @JTOonline @OncoAlert @drgandara @MEArcila @giorgioscaglio3 @lmsholl
0
8
21
@CharuAggarwalMD
Charu Aggarwal, MD, MPH, FASCO
5 years
KRAS Inhibitors show favorable activity in #NSCLC @myESMO Cannot underscore the importance of Molecular Testing in #NSCLC, using tissue or plasma based testing. We discuss this in a recent review @NatRevClinOncol @drgandara @ChristianRolfo @geoff_oxnard @lmsholl Dr. Gray #ESMO20
@Physns1stWatch
PhysiciansFirstWatch
5 years
"Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation." #ESMO20
0
4
19
@lmsholl
Lynette Sholl
5 years
An important read on so many levels: We Can Solve the Coronavirus-Test Mess Now—if We Want To https://t.co/xQzIoQaR5o via @NewYorker
0
0
1
@lmsholl
Lynette Sholl
5 years
Association Between Universal Masking and SARS-CoV-2 Positivity Among Health Care Workers https://t.co/MivSQJyyvf via @JAMA_current part of @JAMANetwork --Universal masking reduces COVID transmission in the hospital @BrighamWomens
0
0
4
@BilalAbidMD
Bilal Abid, MD, MS
5 years
@FranciscoMarty_ @BrighamWomens @lmsholl @DanaFarber @harvardmed @BrighamResearch @ASCAP @damilnermd @onisillos @InfectiousDz SARS-CoV-2 seen in pnuemocytes in 5 and in upper airways in 2. In congruence with preferentially parenchymal ACE2 expression in those at higher risk of severe illness. We are seeing this on ground when IC hosts are testing negative on NP swabs and + only in BAL! #COVID19
0
2
2